Equities analysts expect that Sanofi SA (NYSE:SNY) will report earnings per share of $0.93 for the current quarter, Zacks reports. Zero analysts have made estimates for Sanofi’s earnings. The highest EPS estimate is $0.95 and the lowest is $0.90. Sanofi posted earnings of $1.00 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 7%. The firm is expected to report its next quarterly earnings results before the market opens on Wednesday, October 31st.
According to Zacks, analysts expect that Sanofi will report full year earnings of $3.14 per share for the current financial year, with EPS estimates ranging from $3.13 to $3.15. For the next year, analysts anticipate that the firm will report earnings of $3.32 per share, with EPS estimates ranging from $3.27 to $3.34. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Sanofi.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Tuesday, July 31st. The company reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.02. The business had revenue of $8.18 billion for the quarter, compared to analyst estimates of $8.27 billion. Sanofi had a return on equity of 23.77% and a net margin of 10.29%. Sanofi’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same period last year, the company posted $1.35 earnings per share.
A number of brokerages recently commented on SNY. TheStreet upgraded Sanofi from a “c+” rating to a “b” rating in a report on Thursday, July 12th. BNP Paribas upgraded Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Argus boosted their target price on Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, August 24th. Zacks Investment Research upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, Deutsche Bank restated a “buy” rating on shares of Sanofi in a research note on Wednesday, August 1st. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. Sanofi has a consensus rating of “Hold” and a consensus target price of $49.00.
Sanofi stock traded up $0.59 during mid-day trading on Wednesday, reaching $44.30. 1,658,900 shares of the company’s stock were exchanged, compared to its average volume of 1,920,132. The firm has a market capitalization of $108.85 billion, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 2.33 and a beta of 0.85. Sanofi has a one year low of $37.43 and a one year high of $50.64. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40.
In other Sanofi news, major shareholder Sanofi sold 104,552 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Institute for Wealth Management LLC. grew its position in shares of Sanofi by 27.4% in the second quarter. Institute for Wealth Management LLC. now owns 31,936 shares of the company’s stock valued at $1,278,000 after purchasing an additional 6,860 shares in the last quarter. Providence Capital Advisors LLC grew its position in shares of Sanofi by 46.0% in the second quarter. Providence Capital Advisors LLC now owns 30,016 shares of the company’s stock valued at $1,201,000 after purchasing an additional 9,460 shares in the last quarter. Van ECK Associates Corp grew its position in shares of Sanofi by 15.1% in the second quarter. Van ECK Associates Corp now owns 361,195 shares of the company’s stock valued at $14,451,000 after purchasing an additional 47,420 shares in the last quarter. Clean Yield Group grew its position in shares of Sanofi by 12.0% in the second quarter. Clean Yield Group now owns 108,547 shares of the company’s stock valued at $4,343,000 after purchasing an additional 11,625 shares in the last quarter. Finally, Park Avenue Securities LLC purchased a new position in shares of Sanofi in the second quarter valued at $265,000. Institutional investors own 7.54% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: Investing in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.